Cargando…

An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers

RATIONALE: Working memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D(2) receptors, and this may lead to further dysfunction a...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Anna, Dursun, Serdar, McKie, Shane, Elliott, Rebecca, Deakin, John Francis William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819596/
https://www.ncbi.nlm.nih.gov/pubmed/26900078
http://dx.doi.org/10.1007/s00213-016-4234-9
_version_ 1782425236890714112
author Murphy, Anna
Dursun, Serdar
McKie, Shane
Elliott, Rebecca
Deakin, John Francis William
author_facet Murphy, Anna
Dursun, Serdar
McKie, Shane
Elliott, Rebecca
Deakin, John Francis William
author_sort Murphy, Anna
collection PubMed
description RATIONALE: Working memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D(2) receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D(2) receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory. OBJECTIVES: We probed the implications of the partial D(2) receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D(2)/5-HT(2A) blocker risperidone to separate aripiprazole’s unique prefrontal D(2) agonist actions from its serotinergic and striatal D(2) actions that it shares with risperidone. METHOD: A double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning. RESULTS: Compared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo. CONCLUSION: Aripiprazole has unique DLPFC actions attributed to its prefrontal D(2) agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D(2) blockade. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-016-4234-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4819596
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-48195962016-04-10 An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers Murphy, Anna Dursun, Serdar McKie, Shane Elliott, Rebecca Deakin, John Francis William Psychopharmacology (Berl) Original Investigation RATIONALE: Working memory impairments in schizophrenia have been attributed to dysfunction of the dorsolateral prefrontal cortex (DLPFC) which in turn may be due to low DLPFC dopamine innervation. Conventional antipsychotic drugs block DLPFC D(2) receptors, and this may lead to further dysfunction and working memory impairments. Aripiprazole is a D(2) receptor partial agonist hypothesised to enhance PFC dopamine functioning, possibly improving working memory. OBJECTIVES: We probed the implications of the partial D(2) receptor agonist actions of aripiprazole within the DLPFC during working memory. Investigations were carried out in healthy volunteers to eliminate confounds of illness or medication status. Aripiprazole’s prefrontal actions were compared with the D(2)/5-HT(2A) blocker risperidone to separate aripiprazole’s unique prefrontal D(2) agonist actions from its serotinergic and striatal D(2) actions that it shares with risperidone. METHOD: A double-blind, placebo-controlled, parallel design was implemented. Participants received a single dose of either 5 mg aripiprazole, 1 mg risperidone or placebo before performing the n-back task whilst undergoing fMRI scanning. RESULTS: Compared with placebo, the aripiprazole group demonstrated enhanced DLPFC activation associated with a trend for improved discriminability (d’) and speeded reaction times. In contrast to aripiprazole’s neural effects, the risperidone group demonstrated a trend for reduced DLPFC recruitment. Unexpectedly, the risperidone group demonstrated similar effects to aripiprazole on d’ and additionally had reduced errors of commission compared with placebo. CONCLUSION: Aripiprazole has unique DLPFC actions attributed to its prefrontal D(2) agonist action. Risperidone’s serotinergic action that results in prefrontal dopamine release may have protected against any impairing effects of its prefrontal D(2) blockade. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-016-4234-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-02-22 2016 /pmc/articles/PMC4819596/ /pubmed/26900078 http://dx.doi.org/10.1007/s00213-016-4234-9 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Investigation
Murphy, Anna
Dursun, Serdar
McKie, Shane
Elliott, Rebecca
Deakin, John Francis William
An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title_full An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title_fullStr An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title_full_unstemmed An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title_short An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
title_sort investigation into aripiprazole’s partial d(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819596/
https://www.ncbi.nlm.nih.gov/pubmed/26900078
http://dx.doi.org/10.1007/s00213-016-4234-9
work_keys_str_mv AT murphyanna aninvestigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT dursunserdar aninvestigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT mckieshane aninvestigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT elliottrebecca aninvestigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT deakinjohnfranciswilliam aninvestigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT murphyanna investigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT dursunserdar investigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT mckieshane investigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT elliottrebecca investigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers
AT deakinjohnfranciswilliam investigationintoaripiprazolespartiald2agonisteffectswithinthedorsolateralprefrontalcortexduringworkingmemoryinhealthyvolunteers